Taysha Gene Therapies Inc (TSHA) Directors and Executive Officers

Sean Stalfort
Director

Alison Long, M.D., Ph.D.
Director

Sean Nolan
Chief Executive Officer and Director (Principal Executive Officer)

Phillip B. Donenberg
Director

Kamran Alam
Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)

Laura Sepp-Lorenzino, Ph.D.
Director

Sukumar Nagendran, M.D.
Director ,

Taysha Gene Therapies Inc currently has 99 employees.

News about Taysha Gene Therapies Inc Key Personnel

Taysha Gene Therapies Strives for Talent Amidst Financial Turmoil: A Path to Recovery or a Risky Gamble,

Taysha Gene Therapies: A Balancing Act Between Talent Acquisition and Financial StrugglesIn the ever-evolving landscape of biotechnology, Taysha Gene Therapies, Inc. (NASDAQ: TSHA) has recently taken center stage for a series of significant moves that highlight both ambition and concern. On November 1, 2024, the company’s Compensation Committee granted stock options amounting to 157,000 shares to three new employees, a decision rooted in its 2023 Inducement Plan and guided by Nasdaq Listing Rule 5635(c)(4). This latest incentive follows a broader trend at Taysha, which has made multiple inducement grants this year to attract and retain talent amidst mounting financial difficulties.These grants are not mer...

Taysha Gene Therapies Grants Inducement Options to New Employees in Effort to Advance CNS Gene Therapies – Share Price Sees Q3 Dip

Tays...

Taysha Gene Therapies: Struggles in the Gene Therapy Market Amidst Inducement Grants and Financial Setbacks

Taysha Gene Therapies, a clinical-stage biotech company specializing in gene therapies for severe monogenic diseases of the central nervous system, has recently made significant announcements regarding its operations. On July 3, 2024, the company granted four new employees options to purchase 484,000 shares of its common stock as an inducement for their recruitment. Meanwhile, Taysha Gene Therapies faced considerable financial difficulties, incurring a net loss of $215 million during the 12-month period ending in the third quarter of 2023. This negative return on investment (ROI) of -1104.79% raises concerns about the company s financial stability and overall performance. Let s delve into these fac...

Taysha Gene Therapies Provides Update on Deprioritized Pipeline Programs: An Effort to Enhance Development Potential

Introduction
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a prominent clinical-stage gene therapy company specializing in AAV-based gene therapies for central nervous system (CNS) monogenic diseases, has recently shared an update on its deprioritized pipeline programs. The company aims to provide further support and opportunities for the potential development of these programs in its ongoing efforts. Despite recording a cumulative net loss of $-215 million during the 12 months ending in the third quarter of 2023, resulting in a negative return on investment (ROI) of -1104.79%, Taysha Gene Therapies Inc shares continue to trade on the NASDAQ slightly above its 52-week average.
The Deprioritized Pi...

Taysha Gene Therapies Inc

Officers & Directors

News about Taysha Gene Therapies Inc Key Personnel

Taysha Gene Therapies Strives for Talent Amidst Financial Turmoil: A Path to Recovery or a Risky Gamble,

Taysha Gene Therapies Grants Inducement Options to New Employees in Effort to Advance CNS Gene Therapies – Share Price Sees Q3 Dip

Taysha Gene Therapies: Struggles in the Gene Therapy Market Amidst Inducement Grants and Financial Setbacks

Taysha Gene Therapies Provides Update on Deprioritized Pipeline Programs: An Effort to Enhance Development Potential